United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$417.57 USD
+7.70 (1.88%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $419.09 +1.52 (0.36%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UTHR 417.57 +7.70(1.88%)
Will UTHR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?
Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?
Other News for UTHR
UTHR makes New 52 Week Closing High on September 19
Director’s Major Stock Sale at United Therapeutics!
UTHR forms Golden Cross on September 18
Insider Sell: Judy Olian Sells Shares of United Therapeutics Corp (UTHR)
UTHR forms 180 Bullish Setup on September 17